My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 1034

    1.

    Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes.

    Miyazaki Y, Matsuda M, DeFronzo RA.

    Diabetes Care. 2002 Mar;25(3):517-23.PMID: 11874940 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.

    Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA.

    Diabetes Care. 2001 Apr;24(4):710-9.PMID: 11315836 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.

    Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA.

    J Clin Endocrinol Metab. 2002 Jun;87(6):2784-91.PMID: 12050251 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.

    Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA.

    J Clin Endocrinol Metab. 2004 Sep;89(9):4312-9.PMID: 15356026 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

    Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, Schneider RL.

    Diabetes Care. 2000 Nov;23(11):1605-11.PMID: 11092281 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.

    Rosenblatt S, Miskin B, Glazer NB, Prince MJ, Robertson KE; Pioglitazone 026 Study Group.

    Coron Artery Dis. 2001 Aug;12(5):413-23.PMID: 11491207 [PubMed - indexed for MEDLINE]Related articles

    7.

    Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.

    Miyazaki Y, Glass L, Triplitt C, Matsuda M, Cusi K, Mahankali A, Mahankali S, Mandarino LJ, DeFronzo RA.

    Diabetologia. 2001 Dec;44(12):2210-9.PMID: 11793023 [PubMed - indexed for MEDLINE]Related articles

    8.

    Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.

    Miyazaki Y, DeFronzo RA.

    Diabetes Obes Metab. 2008 Dec;10(12):1204-11. Epub 2008 May 12.PMID: 18476983 [PubMed - indexed for MEDLINE]Related articles

    9.

    Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.

    Derosa G, Cicero AF, Gaddi A, Ragonesi PD, Fogari E, Bertone G, Ciccarelli L, Piccinni MN.

    Clin Ther. 2004 May;26(5):744-54.PMID: 15220018 [PubMed - indexed for MEDLINE]Related articles

    10.

    Bromocriptine: a novel approach to the treatment of type 2 diabetes.

    Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, Pipek R, Iozzo P, Lancaster JL, Cincotta AH, DeFronzo RA.

    Diabetes Care. 2000 Aug;23(8):1154-61.PMID: 10937514 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

    Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

    Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

    12.

    Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.

    Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA.

    Diabetes. 2003 Jun;52(6):1364-70.PMID: 12765945 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.

    Herz M, Johns D, Reviriego J, Grossman LD, Godin C, Duran S, Hawkins F, Lochnan H, Escobar-Jiménez F, Hardin PA, Konkoy CS, Tan MH.

    Clin Ther. 2003 Apr;25(4):1074-95.PMID: 12809958 [PubMed - indexed for MEDLINE]Related articles

    14.

    Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.

    Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, Maffioli P, Cicero AF.

    Metabolism. 2008 Nov;57(11):1552-7.PMID: 18940393 [PubMed - indexed for MEDLINE]Related articles

    15.

    Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.

    Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL.

    Clin Ther. 2000 Dec;22(12):1395-409.PMID: 11192132 [PubMed - indexed for MEDLINE]Related articles

    16.

    Thiazolidinediones improve beta-cell function in type 2 diabetic patients.

    Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA.

    Am J Physiol Endocrinol Metab. 2007 Mar;292(3):E871-83. Epub 2006 Nov 14.PMID: 17106061 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

    Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

    J Clin Pharm Ther. 2006 Aug;31(4):375-83.PMID: 16882108 [PubMed - indexed for MEDLINE]Related articles

    18.

    Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.

    Bajaj M, Suraamornkul S, Piper P, Hardies LJ, Glass L, Cersosimo E, Pratipanawatr T, Miyazaki Y, DeFronzo RA.

    J Clin Endocrinol Metab. 2004 Jan;89(1):200-6.PMID: 14715850 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.

    Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S; Pioglitazone 014 Study Group.

    Int J Clin Pract. 2002 May;56(4):251-7.PMID: 12074206 [PubMed - indexed for MEDLINE]Related articles

    20.

    The effect of pioglitazone on the liver: role of adiponectin.

    Gastaldelli A, Miyazaki Y, Mahankali A, Berria R, Pettiti M, Buzzigoli E, Ferrannini E, DeFronzo RA.

    Diabetes Care. 2006 Oct;29(10):2275-81.PMID: 17003306 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity